The Battle in the War Against Drug Resistant Bacteria

By Research and Markets, Special for  USDR

Research and  Markets

(http://www.researchandmarkets.com/research/crnqlx/antibiotic) has announced the addition of the “Antibiotic Renaissance: Technology and Market Advances in the War against Drug-resistant Bacteria” report to their  offering.

This report covers evolutionary growth of antibiotic resistant bacteria with a focus in research aspects, commercial aspects, market aspects, and trends in antibiotic resistance. Antibiotic resistance has a historical presence in the big pharma industry (documentation of its understanding leads back to 1940); however it has only recently been on the incline of popular adoption. Because of the rapid development of antibiotics and the growing pharma industry, most professionals felt secure in the belief that for every antibiotic fallen by the wayside, new ones would emerge to replace them, much to the chagrin of the smaller population of physicians and medical scientists. Due to technical difficulty, regulatory complexity, and relatively poor returns on investment, commercial drug developers became progressively less enamored with nurturing the antibiotic industry. One by one, big pharmas dropped out of the bacterial infectious disease space in favor of therapeutic areas offering greater blockbuster  potential.

Although researchers have reached a point to develop antibiotics to drug-resistant bacteria, the morbidity and mortality from drug-resistant infections have scourged a variety of regions and industries, including our most useful medical facilities. In an effort to raise awareness and take action, governments, professional societies, and a growing body of medical researchers have published papers and reports that highlight the problems, call for remedial action, and propose action plans. Accordingly, academic, governmental, and commercial players have begun to ramp up activities in response to these calls to  arms.

Highlighted in this report are the following  concepts:

  • History, status, and progress of drug resistant bacteria
  • Evolution of today’s antibiotic resistant bacteria
  • Diagnostic and therapeutic research programs directed at alleviating medical problems caused by antibiotic resistant bacteria
  • Survey results exploiting commercial diagnostic and therapeutic programs and market-related aspects of antibiotic resistance
  • Trends developing in the field
  • Exclusive interviews with six individuals who are highly knowledgeable in the subject area

Key Topics Covered:

Executive Summary

  • Research Aspects Of Antibiotic  Resistance
  • Commercial Aspects Of Antibiotic  Resistance
  • Market Aspects
  • Trends In Antibiotic Resistance

Chapter 1: Introduction

Chapter 2: History And Background

Chapter 3: Research Aspects Of Antibiotic Resistance

Chapter 4: Commercial Aspects Of Antibiotic Resistance

Chapter 5: Market Aspects Of Antibiotic Resistance

Chapter 6: Trends In Antibiotic Resistance

Chapter 7: Interview Transcripts

Companies Mentioned:

  • Accelerate Diagnostics
  • Achaogen
  • Achillion Pharmaceuticals
  • Affinium Pharmaceuticals
  • Alere
  • Allecra Therapeutics
  • Astrazeneca
  • Atlas Genetics
  • Axela Inc. And Hutman Diagnostics
  • Basilea Pharmaceutical
  • Bd Diagnostics
  • Biofire
  • Biota Pharmaceuticals
  • Cellceutix
  • Cempra Pharmaceuticals
  • Cepheid
  • Contrafect
  • Cubist Pharmaceuticals
  • Culture-Based Approaches
  • Curetis
  • Diatherix
  • Durata Therapeutics
  • Elitech Molecular Diagnostics
  • Enanta Pharmaceuticals
  • Forest Laboratories
  • Glaxosmithkline
  • Great Basin Corporation
  • Helperby Therapeutics
  • Johnson & Johnson
  • Mass Spectrometry-Based Diagnostics
  • Melinta Therapeutics
  • Merck
  • Mobidiag
  • Molecular Detection Inc.
  • Nabriva Therapeutics
  • Novolytics
  • Paratek Pharmaceuticals
  • Pfizer
  • Phico Therapeutics
  • Polyphor Ltd.
  • Q-Linea Ab
  • Roche Molecular Systems
  • Shionogi And Co., Ltd.
  • Stat-Diagnostica
  • Taigen Biotechnology
  • Tetraphase Pharmaceuticals
  • The Medicines Company
  • Therapeutic Products And Projects

For more information visit  http://www.researchandmarkets.com/research/crnqlx/antibiotic

All opinions expressed on USDR are those of the author and not necessarily those of US Daily Review.